Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA   3:59:57 PM EDT
97.09
-0.08 (-0.08%)
Products

Reata Pharmaceuticals Plans NDA Submission For Omaveloxolone In Q1 Of 2022 Following Completion Of Pre-NDA Meeting With FDA

Published: 09/30/2021 11:09 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-nda Meeting With FDA.
Reata Pharmaceuticals Inc - Not Planning to Conduct a Second Pre-approval Clinical Study Prior to Submission.